title: Growth-promoting effect of recombinant human growth hormone and stanozolol in girls with Turner syndrome.
abstract: Ten girls with Turner syndrome were treated with a combination therapy of recombinant human growth hormone (R-hGH) and low dose stanozolol for a period of 8 to 36 months. The results showed that when compared with the growth rate before the treatment, the growth rates after treatment with R-hGH and stanozolol showed a sustained increase, reaching 9.0 +/- 1.9 cm/year during the first year of treatment; the height age increase by 2.5 +/- 0.8 years while the bone age increase were 1.0 +/- 0.7 years; and the predicted final adult height at the end of the first year of the treatment increased to 149.4 +/- 6.1 cm compared to their original mean of 142.8 +/- 4.2 cm. We are led to conclude that therapy with R-hGH in combination with stanozolol can increase the growth velocity and significantly increase the predicted adult height of children with Turner syndrome.
authors.affiliation: Department of Pediatrics, Tongji Hospital, Tongji Medical University, Wuhan 430030.
authors.forename: J
authors.initials: J
authors.lastname: Fang
authors.forename: C
authors.initials: C
authors.lastname: Ning
authors.forename: D
authors.initials: D
authors.lastname: Shu
authors.forename: H
authors.initials: H
authors.lastname: Wei
authors.forename: H
authors.initials: H
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D045930:Anabolic Agents / Q000627:therapeutic use; D001827:Body Height / Q000187:drug effects*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D013197:Stanozolol / Q000627:therapeutic use*; D014424:Turner Syndrome / Q000188:drug therapy*
chemical_list: D045930:Anabolic Agents; D013197:Stanozolol; D013006:Growth Hormone